达格列净治疗不合并糖尿病的非阵发性房颤患者的临床效果  

Clinical effect of dapagliflozin in the treatment of non-paroxysmal atrial fibrillation patients without diabetes mellitus

作　　者：牛壮壮 孟影 周跟东 付敏敏 刘梅 高斐 NIU Zhuangzhuang;MENG Ying;ZHOU Gendong;FU Minmin;LIU Mei;GAO Fei(Graduate School of Anhui Medical University,Hefei 230032;Cardiovascular Medicine Department,the Third Affiliated Hospital of Anhui Medical University/Hefei First People′s Hospital,Hefei 230061,China)

机构地区：[1]安徽医科大学研究生学院,安徽合肥230032 [2]安徽医科大学第三附属医院/合肥市第一人民医院心血管内科,安徽合肥230061

出　　处：《临床医学研究与实践》2025年第6期61-64,共4页Clinical Research and Practice

基　　金：2022年安徽医科大学校科研基金项目(No.2022xkj242)。

摘　　要：目的 探究达格列净治疗不合并糖尿病的非阵发性房颤(AF)患者的临床效果。方法 选择2023年1月至2024年2月收治的230例不合并糖尿病的非阵发性AF患者为研究对象,采用随机数字表法将其分为对照组与试验组,各115例。对照组给予常规药物治疗,试验组在对照组基础上联合应用达格列净。比较两组的治疗效果。结果 治疗后,两组的欧洲心律协会(EHRA)评分低于治疗前,6 min步行距离大于治疗前,且试验组优于对照组(P<0.05)。治疗后,两组的左心房前后径、左心房容积指数、二尖瓣舒张早期血流峰值速度与二尖瓣环舒张早期运动峰值速度比值(E/e')均低于治疗前,左心室射血分数高于治疗前,且试验组优于对照组(P<0.05)。治疗后,两组的转化生长因子-β1(TGF-β1)、可溶性生长刺激表达基因2蛋白(sST2)、Ⅲ型前胶原氨基末端肽(PⅢNP)水平均低于治疗前,且试验组低于对照组(P<0.05)。治疗后,两组的白细胞介素-33(IL-33)、C反应蛋白(CRP)水平及中性粒细胞与淋巴细胞计数比值(NLR)均低于治疗前,且试验组低于对照组(P<0.05)。结论 达格列净可降低不合并糖尿病的非阵发性AF患者疾病症状对日常活动的影响,改善心功能、心肌纤维化指标,减轻机体炎症反应。Objective To explore the clinical effect of dapagliflozin in the treatment of non-paroxysmal atrial fibrillation(AF)patients without diabetes mellitus.Methods A total of 230 non-paroxysmal AF patients without diabetes mellitus who were admitted from January 2023 to February 2024 were selected as the research objects.The patients were divided into control group and experimental group by random number table method,with 115 cases in each group.The control group was given routine drug treatment,and the experimental group was combined with dapagliflozin on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the European Heart Rhythm Association(EHRA)score of the two groups was lower than that before treatment,the 6 min walking distance was greater than that before treatment,and those in the experimental group were better than the control group(P<0.05).After treatment,the left atrial anteroposterior diameter,left atrial volume index and the ratio of the peak velocity of early diastolic systolic blood flow and the peak velocity of mitral annulus early dilation(E/e')of the two groups were lower than those before treatment,the left ventricular ejection fraction was higher than that before treatment,and those in the experimental group were better than the control group(P<0.05).After treatment,the levels of transforming growth factor-β1(TGF-β1),soluble growth stimulating express gene 2(sST2)and procollagen typeⅢamino-terminal peptide(PⅢNP)in the two groups were lower than those before treatment,and those in the experimental group were lower than the control group(P<0.05).After treatment,the levels of interleukin-33(IL-33),C-reactive protein(CRP)and neutrophil to lymphocyte ratio(NLR)in the two groups were lower than those before treatment,and those in the experimental group were lower than the control group (P<0.05). Conclusion Dapagliflozin can reduce the impact of disease symptoms on daily activities in non-paroxysmal AF patients without diabetes mellitus, i

关 键 词：非阵发性房颤 达格列净 心功能 

分 类 号：R541.7[医药卫生—心血管疾病]